je.st
news
Takeda's Entyvio and J&J's Stelara to represent new players entering...
2015-01-02 06:40:48| Food - Topix.net
These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade and Humira .The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospiras Inflectra a Remicade biosimilar.
Tags: players
represent
entering
jjs
Category:Food and Related Products